Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 1394 | 2.69 |
09:34 ET | 300 | 2.68 |
09:36 ET | 200 | 2.655 |
09:38 ET | 492 | 2.64 |
09:41 ET | 784 | 2.6794 |
09:50 ET | 100 | 2.67 |
09:52 ET | 100 | 2.66 |
09:54 ET | 400 | 2.655 |
09:56 ET | 400 | 2.655 |
09:59 ET | 400 | 2.645 |
10:01 ET | 100 | 2.64 |
10:03 ET | 200 | 2.63 |
10:08 ET | 400 | 2.61 |
10:10 ET | 342 | 2.61 |
10:14 ET | 1380 | 2.62 |
10:17 ET | 400 | 2.61 |
10:19 ET | 709 | 2.63 |
10:28 ET | 652 | 2.62 |
10:37 ET | 100 | 2.63 |
10:42 ET | 300 | 2.64 |
10:44 ET | 100 | 2.62 |
10:48 ET | 100 | 2.63 |
10:50 ET | 100 | 2.63 |
10:53 ET | 100 | 2.63 |
10:55 ET | 100 | 2.63 |
11:00 ET | 300 | 2.63 |
11:02 ET | 100 | 2.63 |
11:04 ET | 200 | 2.635 |
11:06 ET | 100 | 2.635 |
11:08 ET | 331 | 2.6386 |
11:09 ET | 200 | 2.63 |
11:24 ET | 466 | 2.6351 |
11:26 ET | 100 | 2.6371 |
11:27 ET | 200 | 2.635 |
11:31 ET | 400 | 2.63 |
11:33 ET | 100 | 2.635 |
11:38 ET | 200 | 2.635 |
11:40 ET | 300 | 2.6399 |
11:42 ET | 100 | 2.63 |
11:44 ET | 17318 | 2.65 |
11:49 ET | 100 | 2.64 |
11:51 ET | 500 | 2.64 |
11:54 ET | 325 | 2.64 |
11:56 ET | 100 | 2.64 |
11:58 ET | 400 | 2.64 |
12:00 ET | 200 | 2.63 |
12:02 ET | 100 | 2.63 |
12:03 ET | 100 | 2.63 |
12:05 ET | 100 | 2.63 |
12:09 ET | 100 | 2.63 |
12:14 ET | 100 | 2.63 |
12:16 ET | 100 | 2.64 |
12:18 ET | 100 | 2.63 |
12:21 ET | 773 | 2.65 |
12:23 ET | 413 | 2.67 |
12:25 ET | 300 | 2.68 |
12:27 ET | 200 | 2.69 |
12:34 ET | 200 | 2.68 |
12:38 ET | 2749 | 2.67 |
12:45 ET | 700 | 2.665 |
12:48 ET | 200 | 2.665 |
12:56 ET | 1240 | 2.66 |
12:59 ET | 100 | 2.65 |
01:08 ET | 300 | 2.65 |
01:14 ET | 200 | 2.64 |
01:17 ET | 400 | 2.65 |
01:19 ET | 300 | 2.65 |
01:26 ET | 100 | 2.64 |
01:28 ET | 1246 | 2.645 |
01:30 ET | 100 | 2.63 |
01:32 ET | 177 | 2.63 |
01:33 ET | 100 | 2.63 |
01:37 ET | 100 | 2.63 |
01:42 ET | 100 | 2.63 |
01:46 ET | 100 | 2.63 |
01:50 ET | 3541 | 2.6401 |
01:53 ET | 300 | 2.645 |
01:55 ET | 950 | 2.645 |
01:57 ET | 2876 | 2.63 |
02:00 ET | 100 | 2.63 |
02:04 ET | 3762 | 2.61 |
02:06 ET | 100 | 2.6 |
02:08 ET | 100 | 2.6 |
02:11 ET | 1199 | 2.6 |
02:13 ET | 666 | 2.61 |
02:15 ET | 1099 | 2.61 |
02:20 ET | 1100 | 2.6053 |
02:22 ET | 200 | 2.605 |
02:24 ET | 300 | 2.61 |
02:26 ET | 1472 | 2.6 |
02:31 ET | 100 | 2.605 |
02:33 ET | 720 | 2.61 |
02:49 ET | 100 | 2.61 |
02:54 ET | 100 | 2.61 |
03:00 ET | 100 | 2.615 |
03:03 ET | 1500 | 2.6 |
03:05 ET | 100 | 2.59 |
03:07 ET | 200 | 2.6 |
03:09 ET | 100 | 2.6 |
03:12 ET | 300 | 2.6 |
03:14 ET | 1140 | 2.59 |
03:16 ET | 310 | 2.6 |
03:18 ET | 2097 | 2.62 |
03:21 ET | 100 | 2.62 |
03:27 ET | 200 | 2.62 |
03:32 ET | 400 | 2.62 |
03:34 ET | 200 | 2.62 |
03:36 ET | 300 | 2.61 |
03:38 ET | 1666 | 2.62 |
03:39 ET | 100 | 2.61 |
03:41 ET | 200 | 2.63 |
03:43 ET | 200 | 2.62 |
03:45 ET | 200 | 2.61 |
03:48 ET | 200 | 2.61 |
03:50 ET | 600 | 2.62 |
03:52 ET | 1431 | 2.61 |
03:54 ET | 1401 | 2.61 |
03:56 ET | 3074 | 2.61 |
03:57 ET | 6056 | 2.615 |
03:59 ET | 33656 | 2.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 137.1M | -0.6x | --- |
Acumen Pharmaceuticals Inc | 140.0M | -2.2x | --- |
Atossa Therapeutics Inc | 140.8M | -4.7x | --- |
Boundless Bio Inc | 133.1M | 0.0x | --- |
Cytodyn Inc | 133.1M | -2.4x | --- |
Tevogen Bio Holdings Inc | 132.5M | -1,855.1x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $137.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.37 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.